• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=20406486).
  
• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486).
  

PubMed=20406486; DOI=10.1186/1479-5876-8-39
Sondergaard J.N., Nazarian R., Wang Q., Guo D.-L., Hsueh T., Mok S., Sazegar H., MacConaill L.E., Barretina J.G., Kehoe S.M., Attar N., von Euw E.M., Zuckerman J.E., Chmielowski B., Comin-Anduix B., Koya R.C., Mischel P.S., Lo R.S., Ribas A.
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
J. Transl. Med. 8:39.1-39.11(2010)

PubMed=20689758; DOI=10.1593/neo.10414
Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G., Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Neoplasia 12:637-649(2010)

PubMed=22515704; DOI=10.1186/1476-4598-11-22
von Euw E.M., Atefi M., Attar N., Chu C., Zachariah S., Burgess B.L., Mok S., Ng C., Wong D.J.L., Chmielowski B., Lichter D.I., Koya R.C., McCannel T.A., Izmailova E., Ribas A.
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.
Mol. Cancer 11:22.1-22.9(2012)

PubMed=24735930; DOI=10.1186/1476-4598-13-83
Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M., Comin-Anduix B., Ribas A.
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Mol. Cancer 13:83.1-83.14(2014)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)